Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 06 Nov, 13:56 UTC

A priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies. The post Why Glycosylation Control Is No Longer a…

science

Sources

• T2Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex BiologicsFierce Biotech / Fierce Healthcare / MedCity / GEN06 Nov, 13:56